Source: PR Newswire via Yahoo! Finance
Posted: May 31, 2006 10:36 am ET
Summary:
The Juvenile Diabetes Research Foundation announced that it has established a partnership with Novocell, Inc. an Irvine, California-based, biotechnology company, to support an on-going proof of principle phase I/II human clinical trial for Novocell's polyethylene glycol encapsulation of insulin-producing islets.
Novocell's encapsulation technology uniformly coats donated pancreatic islets with a thin layer of biocompatible material. This coating is believed to enable implanted cells to survive and control glucose levels in patients with type 1 diabetes, resulting in near normal hemoglobin levels without the need for life-long immunosuppression.
Commentary: Hopefully this new drug therapie will prove effective in a large population of diabetes patients to be considered and effective treatment for diabetes
No comments:
Post a Comment